{
    "clinical_study": {
        "@rank": "41758", 
        "arm_group": [
            {
                "arm_group_label": "Calcipotriol", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week."
            }, 
            {
                "arm_group_label": "Calcipotriol plus Nicotinamide", 
                "arm_group_type": "Experimental", 
                "description": "Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine if combination of topical calcipotriol and nicotinamide is more\n      effective than calcipotriol alone in treatment of psoriasis."
        }, 
        "brief_title": "Nicotinamide in the Treatment of Psoriasis", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting\n      inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments.\n      Preliminary studies have shown that nicotinamide, which is a vitamin B derivative, is\n      effective in the treatment of psoriasis. According to lack of data, we will investigate the\n      beneficial effects of adding nicotinamide to calcipotriol for patients with mild to moderate\n      psoriasis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women of 18 to 65 years old,\n\n          -  Mild to moderate psoriasis; patients must have had less than 15% of the involved body\n             surface, symmetrical plaques (bilateral lesions) or two plaques at least 5 cm apart\n             on the same side of the body with plaque size greater than 2 \u00d7 2 cm, but smaller than\n             15 \u00d7 15 cm.\n\n          -  Willingness to participate\n\n        Exclusion Criteria:\n\n          -  Those who used any medication or niacin and multi-vitamins two weeks, or\n             anti-psoriatic systemic drugs or beta-blockers one month prior to the study,\n\n          -  Pregnant women,\n\n          -  Those with the history of renal, hematologic, liver and major psychiatric diseases,\n\n          -  Those with only scalp, nail, flexural, palmoplantar, or pustular psoriasis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763424", 
            "org_study_id": "390134"
        }, 
        "intervention": [
            {
                "arm_group_label": "Calcipotriol plus Nicotinamide", 
                "description": "Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.", 
                "intervention_name": "Calcipotriol plus Nicotinamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Calcipotriol", 
                "description": "Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.", 
                "intervention_name": "Calcipotriol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Niacinamide", 
                "Niacin", 
                "Nicotinic Acids", 
                "Calcitriol", 
                "Calcipotriene"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Skin Diseases and Leishmaniasis Research Center"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis.", 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Mehdi Khodadadi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients are visited by a dermatologist at baseline and then after the first and third month of therapy, and psoriasis severity is evaluated using the modified psoriasis area and severity index.", 
            "measure": "Psoriasis severity", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 months"
        }, 
        "reference": {
            "PMID": "20599292", 
            "citation": "Levine D, Even-Chen Z, Lipets I, Pritulo OA, Svyatenko TV, Andrashko Y, Lebwohl M, Gottlieb A. Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. J Am Acad Dermatol. 2010 Nov;63(5):775-81. doi: 10.1016/j.jaad.2009.10.016."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763424"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Dr. Mehdi Khodadadi", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patient's satisfaction is evaluated at the end of the trial using a 10-point rating scale.", 
            "measure": "Patient's satisfaction", 
            "safety_issue": "No", 
            "time_frame": "After 3 months"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}